Scancell presenting at 21st CIMT Annual Meeting
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that multiple abstracts have been accepted for an oral and as poster presentations at the 21st Association for Cancer Immunotherapy CIMT Annual Meeting being, taking place in Mainz, Germany, on 15-17 May 2024.
Impressive clinical data of SCIB1, supported by functional T cell responses to the TRP2 and gp100 peptides which can be detected in patients post vaccination, will be presented by Head of Translational Research, Dr Samantha Paston. The posters will show the isolation of specific TCRs that recognise post translationally modified peptides and the application of Anti-Sialyl-di-Lewis-a as a CAR-T. Professor Lindy Durrant, Chief Executive Officer of Scancell. "We are thrilled to have a robust presence at this year's CIMT meeting. These presentations are a reflection of Scancell's high quality science and expertise in developing innovative immunotherapies to address unmet needs in cancer."
CIMT is Europe's largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.
Oral Presentation details are as follows:
Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma
Session: Short talk session VI
Date and Time: Thursday, 17th May 2024 between 10.30am-12.00pm
Location: Rheingoldhalle Congress Center Mainz
Abstract No: 139
Speaker: Dr Samantha Paston
Authors: Samantha Paston, Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Robert Miller, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Victoria Brentville, Rachael Metheringham, Georgia Goodhew, Fayaz Master, Lindy Durrant.
Poster Presentation details are as follows:
Title: Isolation and characterisation of TCRs that recognise Citrullinated and Homocitrullinated post translationally modified peptides
Session Poster session I
Date and Time Wednesday, 15th May 2024 between 3.00pm-5.30pm
Location Rheingoldhalle Congress Center Mainz
Abstract No: 34
Authors: Samantha Paston, Ruhul Choudhury, Sabaria Shah, Gaëlle Cane, Joseph Chadwick, Rachael Metheringham, Fayaz Master, Rebecca Herbertson, Lindy Durrant.
Title: Anti-Sialyl-di-Lewisa CAR T cells for effective tumor therapy of gastrointestinal tumor
Session Poster session I
Date and Time Wednesday, 15th May 2024 between 3.00pm-5.30pm
Location Rheingoldhalle Congress Center Mainz
Abstract No: 5
Authors: I. Charles, K. Cook, G. Cane, B. Kaira, A. Skinner, A. Wright, M. Vankemmelbeke, R. Metheringham, V. Brentville, L. Durrant
The posters will be made available on the Company's website following the conference at https://www.scancell.co.uk/antibody-publications
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.